Tumor mutation burden offers a promising predictive biomarker for patients with small cell lung cancer. An exploratory analysis presented at the World Conference on Lung Cancer showed that the patients with large numbers of mutations in their cancer cells were more likely to respond—and for a longer time—to a single checkpoint inhibitor or a combination of them than those with a low mutation load.

中文翻译：

---

突变负载在SCLC中提供生物标记

肿瘤突变负担为小细胞肺癌患者提供了有希望的预测性生物标志物。在世界肺癌大会上进行的一项探索性分析表明，癌细胞中具有大量突变的患者对单检查点抑制剂或它们的组合的反应比对那些接受检查的抑制剂更可能（更长的时间）。突变负荷低。